Details for New Drug Application (NDA): 020338
✉ Email this page to a colleague
The generic ingredient in DIFFERIN is adapalene. There are twelve drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the adapalene profile page.
Summary for 020338
Tradename: | DIFFERIN |
Applicant: | Galderma Labs Lp |
Ingredient: | adapalene |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020338
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;TOPICAL | Strength | 0.1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | May 31, 1996 | TE: | RLD: | Yes |
Expired US Patents for NDA 020338
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Galderma Labs Lp | DIFFERIN | adapalene | SOLUTION;TOPICAL | 020338-001 | May 31, 1996 | 4,717,720 | ⤷ Subscribe |
Galderma Labs Lp | DIFFERIN | adapalene | SOLUTION;TOPICAL | 020338-001 | May 31, 1996 | RE34440 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription